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Although endothelin (ET)-1 is a highly potent vasoconstrictor with considerable efficacy
in numerous vascular beds, the role of endogenous ET-1 in the regulation of vascular
tone remains unclear. The perspective that ET-1 plays little role in the on-going regulation
of vascular tone at least under physiologic conditions is supported by findings that
potential ET-1 constriction is minimized by the release of the vasodilator and ET-1
synthesis inhibitor, nitric oxide (NO). Indeed, ET-1 release and constriction is self-limited
by ET-1-induced, endothelial ETB receptor-mediated release of NO. Moreover, even if
the balance between ET-1 and NO were reversed as the result of lowered NO activity,
as occurs in a number of pathophysiologies associated with endothelial dysfunction, the
well-known resistance of ET-1 constriction to reversal (as determined with exogenous
ET-1) precludes ET-1 in the dynamic, i.e., moment-to-moment, regulation of vascular
tone. On the other hand, and as presently reviewed, findings of ET-1-dependent
modulation of organ blood flow with exercise under physiologic conditions demonstrate
the dynamic regulation of vascular tone by ET-1. We speculate that this regulation is
mediated at least in part through changes in ET-1 synthesis/release caused by pulsatile
flow-induced shear stress and NO.
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INTRODUCTION
There is substantial evidence that increased release of the potent vasoconstrictor, endothelin (ET)-
1, underlies the sustained elevated vascular tone in numerous pathophysiologies associated with
endothelial dysfunction (Félétou and Vanhoutte, 2000; De Mey and Vanhoutte, 2014). In contrast,
there is considerably less support for ET-1 in the regulation of vascular tone under physiologic
conditions (Félétou and Vanhoutte, 2000; De Mey and Vanhoutte, 2014) although notable amongst
this support is (1) endothelial ETB receptor-mediated lowering of arterial pressure, due to nitric
oxide (NO) release and ET-1 clearance (de Nucci et al., 1988; Gratton et al., 1997; Lavallée et al.,
2001; Bourque et al., 2011; Kelland et al., 2010), and (2) ETA and ETA/B receptor-mediated pressure
elevation due to activation of these receptors on smooth muscle, albeit findings of lowered pressure
in response to ETA and ETA/B receptor antagonists are variable (for reviews see Lavallée et al., 2001;
Bourque et al., 2011; Rapoport, 2014a) with, as presently cited, lowered pressure in pig (Merkus
et al., 2002, 2003, 2006, 2007; Houweling et al., 2006; de Beer et al., 2011b; Zhou et al., 2014b)
and in one human study (Mather et al., 2002), but not in other studies in human (Cardillo et al.,
1999; Martin et al., 2002; Thijssen et al., 2007; Barrett-O’Keefe et al., 2013, 2015), and neither
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in dog (Thorin et al., 1999; Takamura et al., 2000) and rat
(Maeda et al., 2002). The apparent limited role for ET-1
regulation of vascular tone under physiological conditions has
been attributed in part to possible minimization of any potential
ET-1 constriction by NO, which causes both vasodilation and
inhibits ET-1 synthesis (Vanhoutte, 2000; De Mey and Vanhoutte,
2014).
Moreover, even if ET-1 were to regulate arterial pressure, this
effect would presumably be on a sustained rather than dynamic,
i.e., moment-to-moment basis (Félétou and Vanhoutte, 2000; De
Mey and Vanhoutte, 2014). This conclusion follows from the
widely reported observation that the ET-1 constriction is highly
resistant to reversal, as demonstrated following intravenous ET-1
bolus and ET-1 washout ex vivo (Yanagisawa et al., 1988; Clarke
et al., 1989a,b; Neubauer et al., 1990; Félétou and Vanhoutte,
2000; Meens et al., 2010, 2011; De Mey and Vanhoutte, 2014).
In apparent contradiction to these general assessments,
however, it appears that with exercise not only does ET-1 serve
as a physiologic regulator of vascular tone but that the regulation
is dynamic (Tables 1, 2). This evidence is presently reviewed and
underlying mechanisms surmised.
ET RECEPTOR ANTAGONIST EFFECTS
ON EXERCISE-INDUCED CHANGES IN
BLOOD FLOW
The effect of ETA/ETA/B receptor antagonists, particularly when
administered systemically, on local flow should be interpreted in
combination with changes in local metabolism when possible.
Autoregulation will attempt to maintain blood flow constant and
hence vascular diameter will vary when blood pressure changes
in response to systemically administered vasodilators.
Heart
Since systemic vasodilation is accompanied by changes in heart
rate and blood pressure, the oxygen demand of the myocardium
is likely to be altered. Optimal methodology for the assessment of
vascular tone is by relating changes in myocardial oxygen supply
to changes in myocardial oxygen demand. When this is not
possible, changes in coronary blood flow and/or diameter of the
large coronary vessels could potentially be used as an indicator
of the vasoactive effects, particularly when ETA/ETA/B receptor
antagonists are infused intracoronarily.
Rest
ETA/ETA/B receptor antagonists increased coronary blood flow
or dilated the coronary vasculature, depending on the species
(Table 1). In dog, although intracoronarily (Thorin et al., 1999)
and intravenously (Takamura et al., 2000) infused ETA and
ETA/B receptor antagonists did not increase coronary flow
(Table 1), infusion dilated the external coronary circumflex artery
(Thorin et al., 1999) and increased coronary sinus O2 saturation,
consistent with coronary dilation (Takamura et al., 2000). ETB
receptor antagonism and NO synthase inhibition did not alter
the diameter of the external coronary circumflex artery, although
coronary flow decreased (Thorin et al., 1999).
In pig, intrapulmonary artery infused ETA and ETA/B receptor
antagonist increased flow/dilated the coronary vascular bed
(Merkus et al., 2002, 2003, 2005, 2006; de Beer et al., 2011b;
Zhou et al., 2014a; Table 1). The magnitude of increase was
slightly, but significantly greater with ETA receptor antagonism
as compared to ETA/B receptor antagonism, suggesting the
presence of underlying endothelial ETB receptor vasodilation
(Merkus et al., 2003; Table 1). Along these lines, although
NO synthase and cyclooxygenase inhibition did not enhance
ETA/B receptor antagonist increased flow, it was speculated that
ischemia due to NO synthase and cyclooxygenase inhibition
resulted in release of a vasodilator, e.g., adenosine, which masked
the decreased flow (Merkus et al., 2006). Indeed, the possibility
that ETA/B receptor antagonist inhibited NO release is supported
by the lack of additivity of the elevated flows by ETA/B receptor
antagonist and an inhibitor of phosphodiesterase-5; the latter
preventing the breakdown of the NO-mediator of vasodilation,
cyclic GMP (Zhou et al., 2014a). Thus, even at rest, the capacity of
the endothelium to synthesize/release ET-1 is reduced by NO. It
should be noted, however, that an increase in ET-1 plasma levels
in the coronary vascular bed (arteriovenous difference) was not
detected following NO synthase inhibition (Merkus et al., 2006).
While an explanation is not clear with respect to the
enhancement and lack of effect of ETA/ETA/B receptor
antagonism on resting flow in the coronary vasculature of the
pig (Merkus et al., 2002, 2003, 2005, 2006) and dog (Thorin
et al., 1999; Takamura et al., 2000), respectively, one possibility is
differences in the regulation of the coronary vasculature in these
species (Merkus et al., 2006, 2008). In this regard, in dog coronary
vasculature, cyclooxygenase and NO synthase inhibition was
without effect and caused minimal constriction, respectively (as
cited in Merkus et al., 2006, 2008). In contrast, in the coronary
vasculature of the pig and, notably, in human, cyclooxygenase
and NO synthase inhibition caused vasoconstriction (Merkus
et al., 2006, 2008).
Exercise
ETA/ETA/B receptor antagonists increased coronary blood flow
and/or dilated the coronary vasculature, depending on the species
(Table 1). In dog, intravenous infused ETA/B receptor antagonist
increased coronary sinus O2 saturation (Takamura et al., 2000),
consistent with coronary dilation, although elevated coronary
flow was not detected (Takamura et al., 2000; Table 1). With
ventricular pacing, which did not increase coronary flow, ETA
and ETA/B receptor antagonists increased the diameter of the
external coronary circumflex artery to a similar magnitude as
observed with these antagonists at rest (Thorin et al., 1999).
NO synthase inhibitor did not alter the ETA and ETA/B
receptor antagonist-increased diameter of the external coronary
circumflex artery with ventricular pacing (Thorin et al., 1999).
In pig, intrapulmonary artery infused ETA and ETA/B receptor
antagonist increased coronary dilation, with the magnitude of
increase slightly but significantly greater with ETA receptor
antagonist at all levels of exercise intensity (Merkus et al.,
2002, 2003, 2005, 2006; de Beer et al., 2011b; Zhou et al.,
2014a; Table 1). With increasing exercise intensity, however, the
additional vasodilator effect due to ETA and ETA/B receptor
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TABLE 1 | Effect of endothelin receptor antagonists on flow in non-primate mammals.
Flow1
Vascular bed Species ETRA Rest + ETRA vs. Rest Exercise vs. Rest Exercise + ETRA vs. Exercise Reference
Coronary Dog ETA/B – ↑ −2 Takamura et al., 2000
Pig ETA ↑ ↑ ↓ Merkus et al., 2002
ETA ↑ ↑ ↓3 Merkus et al., 2003
ETA/B ↑↑ ↑ ↓4
ETA ↑ ↑ ↓3 Merkus et al., 2005
ETA/B ↑ ↑ ↓4
ETA/B ↑ ↑ ↓ Merkus et al., 2006
ETA/B ↑ ↑ ↓4 de Beer et al., 2011b
ETA/B ↑ ↑ ↓4 Zhou et al., 2014a
Lung Pig ETA – ↑ – Merkus et al., 2003
ETA/B – ↑ ↑
ETA – ↑ – Houweling et al., 2006
ETA/B – ↑ ↑
ETA/B – ↑ ↑ Merkus et al., 2007
ETA/B – ↑ ↑ de Beer et al., 2010
ETA/B – ↑ ↑ Zhou et al., 2014b
Skeletal Rat Maeda et al., 2002
Plantaris ETA – ↑ ↓
ETA/B – ↑ ↓
Soleus ETA – ↑ ↓
Tibialis ETA – ↑ ↓
ETA/B – ↑ ↓
Splanchnic Rat
Intestine ETA – ↓ ↑ Maeda et al., 2002
ETA/B – ↓ ↑
ETA – ↓ ↑
ETA/B – ↓ ↑
Spleen ETA – ↓ ↑
ETA/B – ↓ ↑
Stomach ETA – ↓ ↑
ETA/B – ↓ ↑
1Pressure in lungs, 2 Increased coronary sinus O2, 3Waned with exercise intensity, 4Obliterated with exercise intensity, ↑, ↓, – = increase, decrease, no change.
antagonism waned and was obliterated, respectively (Merkus
et al., 2003, 2005; Table 1). As with rest, the magnitude of
increase was slightly but significantly greater with ETA receptor
antagonism as compared to ETA/B receptor antagonism (Merkus
et al., 2003; Table 1). Contrary to the coronary ETA receptor
vasoconstrictor influence that waned with increasing exercise
intensity, the ETB receptor mediation vasodilation was similar at
all exercise intensities (Merkus et al., 2003, 2006).
Despite the underlying ETB receptor mediated vasodilation,
neither NO synthase inhibition nor cyclooxygenase inhibition
enhanced the vasodilation by ETA and ETA/B receptor
antagonism (Merkus et al., 2006). However, in the presence
of inhibitors of NO synthase and/or cyclooxygenase, the
vasodilator effect of ETA/B receptor blockade was sustained with
increasing exercise intensity, with combined inhibition eliciting
additive effects (Merkus et al., 2006). Moreover, in the presence of
NO synthase and cyclooxygenase inhibitors there was a positive
correlation between ETA/B receptor antagonist-increased flow
and exercise intensity (Merkus et al., 2006; de Beer et al., 2011b).
Thus, increased exercise intensity resulted in greater NO- and
prostaglandin-mediated suppression of ET-1-mediated coronary
vasoconstriction (Merkus et al., 2006).
Several findings suggest that the ability of NO synthase
inhibitor to prevent the ETA/B receptor antagonist obliteration
of increased flow is due to reversal of NO inhibition of ET-1
synthesis. Increasing exercise intensity caused a dose-dependent
decrease in ET-1 synthesis in the coronary vasculature, but
not in the systemic circulation, as assessed by the conversion
of big ET-1 to ET-1 (de Beer et al., 2011a). NO synthase
inhibition also increased ET-1 plasma levels in the coronary
vasculature (coronary arteriovenous difference; Merkus et al.,
2006). Decreased ET-1 synthesis with exercise is also consistent
with lowered pre-pro ET-1 mRNA expression in the aorta
following 30 min (shortest duration studied) in the rat
(Maeda et al., 2004). Further, the NO-mediated vasodilation was
not due to decreased ET-1 constriction because contractile
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TABLE 2 | Effect of endothelin receptor antagonists on resting and exercise-elevated flow in humans.
Flow
Muscle Age1 (yrs) Pathophysiology ETRA Rest + ETRA vs. Rest Exercise + ETRA vs. Exercise Reference
Forearm 20–43 ETA ↑↑ n.d. Verhaar et al., 1998
ETA/B ↑ n.d.
47 ETA – n.d. Cardillo et al., 1999
ETA/B – n.d.
51 ETA – n.d. Cardillo et al., 2000
55 Hypercholesterolemia ETA ↑ n.d.
Hypercholesterolemia ETA/B – n.d.
18–30 ETA ↑ n.d. Spratt et al., 2001
48 ETA – n.d. Cardillo et al., 2002
50 Type 2 diabetes ETA ↑ n.d.
Type 2 diabetes ETA/B ↑ n.d.
54 ETA/B ↑ ↑2 Martin et al., 2002
54 Hypertension ETA/B ↑ ↑2
50 ETA ↑ ↑ McEniery et al., 2002
49 Hypertension ETA ↑ ↑↑
483 ETA – n.d. Cardillo et al., 2004
Overweight ETA – n.d.
Obese ETA – n.d.
504 Hypertension ETA – n.d.
Hypertension + Overweight ETA ↑ n.d.
Hypertension + Obese ETA ↑↑ n.d.
55 ETA – n.d. Shemyakin et al., 2006
ETA/B – n.d.
53 Insulin resistance ETA ↑ n.d.
Insulin resistance ETA/B – n.d.
27 ETA – n.d. Van Guilder et al., 2007
62 ETA ↑ n.d.
27 ETA/B – n.d.
62 ETA/B ↑ n.d.
55 ETA – n.d. Weil et al., 2011
56 Overweight ETA ↑ n.d.
57 Obese ETA ↑ n.d.
60 ETA/B – ↑5 Schreuder et al., 2014
60 Type 2 diabetes ETA/B – ↑5
54 ETA – n.d. Dow et al., 2017
56 Overweight/Obese ETA ↑ n.d.
Leg 33 ETA – n.d. Mather et al., 2002
45 Type 2 diabetes ETA ↑ n.d.
34 Obese ETA ↑ n.d.
34 ETA/B – n.d. Thijssen et al., 2007
70 ETA/B ↑ n.d.
24 ETA – ↑ Barrett-O’Keefe et al., 2013, 2015
70 ETA ↑ ↑↑
1Mean or range, 2Plethysmography-induced reactive hyperemia, 3Mean for lean, overweight and obese, 4Mean for hypertensive, hypertensive + overweight and
hypertensive + obese, 5Continuous but not incremental exercise ↑, ↓, –, n.d. = increase, decrease, no change, not determined.
sensitivity to infused exogenous ET-1 remained unaltered with
exercise (de Beer et al., 2011a). Also, phosphodiesterase-5
inhibition and 8-Br-cGMP did not decrease ET-1 constriction,
whereas the endothelium-dependent constriction to big ET-1
was decreased in isolated coronary resistance vessels (Zhou
et al., 2014a). These findings are consistent with NO synthase
inhibitor-increased big ET-1, but not ET-1, constriction of
isolated rat mesenteric artery (Bourque et al., 2012).
Conclusion and Speculation
The ability of ETA and ETA/B receptor antagonists to increase
coronary flow at rest and with exercise demonstrates that ET-1
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dynamically, i.e., on a moment-to-moment basis, limits coronary
flow under both conditions (Table 1). Moreover, the coronary
endothelium has a greater capacity to release ET-1 with increased
exercise intensity, an effect that is limited by NO inhibition of
ET-1 synthesis. Thus, the dynamic regulation of flow by ET-1
is modulated by a dynamic balance between increased ET-1
synthesis and subsequent ET-1 release, and increased inhibition
of ET-1 synthesis by enhanced NO.
It is of interest to consider that a major influence of the balance
between NO and ET-1 is pulsatile shear stress. In this regard, the
coronary bed is exposed to relatively high levels of shear stress
even at rest (Recchia et al., 1996). Indeed, the magnitude of basal
flow in the coronary vascular bed is similar to flow in exercised
skeletal muscle (Laughlin et al., 1996). With increased exercise
intensity, shear stress increases, resulting in further NO release
and lowering ET-1 synthesis (Merkus et al., 2003, 2006; Rapoport,
2014b). Furthermore, it should be considered that along with a
major effect of shear stress to increase NO release, endothelial
ETB receptor activation provides a relatively smaller component
of NO, in particular at higher levels of exercise intensity.
Splanchnic: Intestine, Kidney, Spleen,
and Stomach
Rest
Intra-aortic infused ETA and ETA/B receptor antagonists did
not alter resting flow in intestine, kidney, spleen, and stomach
(Maeda et al., 2002; Table 1).
Exercise
Exercise decreased flow in intestine, kidney, spleen, and stomach
(Maeda et al., 2002; Table 1). The amount of exercise-lowered
flow was reduced by ETA and ETA/B receptor antagonism (Maeda
et al., 2002; Table 1). Similar magnitudes of attenuation of the
decreased flow with exercise were achieved with ETA and ETA/B
receptor antagonists (Maeda et al., 2002; Table 1).
Conclusion and Speculation
Consistent with ET-1 as a dynamic regulator of vascular tone,
is the ETA and ETA/B receptor antagonist reduction of exercise-
induced decreased flow to intestine, kidney, spleen, and stomach
(Maeda et al., 2002; Table 1). Thus, ET-1 appears to regulate
exercise-mediated redistribution of blood flow away from the
splanchnic circulation to other organs, e.g., skeletal muscle (see
below; Maeda et al., 2002). The similar magnitude of ETA
and ETA/B receptor antagonist-mediated reduction of exercise-
induced decreased flow (Maeda et al., 2002; Table 1) suggests that
ET-1 activation of endothelial ETB receptors does not modulate
this reduction.
The lack of effect of ETA and ETA/B receptor antagonism on
resting flow in splanchnic organs is consistent with the lesser
magnitude of sheer stress to which these organs are subjected at
rest as compared to the coronary vascular bed, in which ETA and
ETA/B receptor antagonism increased resting flow (see section
“Heart”; Table 1). That is, ET-1 release is increased with modest
elevations in shear stress and the level of NO release may be
insufficient to counter, through inhibition of ET-1 synthesis, the
increased ET-1 release (Rapoport, 2014b).
Skeletal Muscle
Rest
ETA and ETA/B receptor antagonism were largely without
effect on resting skeletal muscle blood flow in healthy human
volunteers, as demonstrated in the forearm and leg with intra-
brachial artery (Cardillo et al., 1999, 2000, 2002, 2004; Shemyakin
et al., 2006; Van Guilder et al., 2007; Weil et al., 2011;
Schreuder et al., 2014; Dow et al., 2017) and intra-femoral artery
infused antagonist, respectively (Thijssen et al., 2007; Barrett-
O’Keefe et al., 2013, 2015; Table 2). In contrast, other studies
demonstrated increased forearm flow with intra-brachial ETA
and ETA/B receptor antagonist infusion (Verhaar et al., 1998;
Spratt et al., 2001; Martin et al., 2002; McEniery et al., 2002;
Table 2).
An explanation for the contrasting effects of ETA and ETA/B
receptor antagonists on resting flow does not appear to be the
age of the volunteers. Specifically, while ETA/ETA/B receptor
antagonist-increased flow in forearm and leg was restricted
to aged humans (Van Guilder et al., 2007; Barrett-O’Keefe
et al., 2013, 2015; Table 2), others demonstrated increased
forearm flow with ETA/ETA/B receptor antagonism in relatively
younger volunteers (Verhaar et al., 1998; Spratt et al., 2001).
Another possibility is that undetected endothelial dysregulation
is present in otherwise healthy volunteers. Along these lines,
ETA/ETA/B receptor antagonism increased forearm resting flow
in volunteers with hypercholesterolemia, insulin resistance, type
2 diabetes, excessive weight, and combined excessive weight and
hypertension, but not in normal control volunteers (Cardillo
et al., 2000, 2002, 2004; Mather et al., 2002; Shemyakin et al., 2006;
Weil et al., 2011; Dow et al., 2017; Table 2). Possibly in general
support of this explanation is that intra-aorta infused ETA and
ETA/B receptor antagonists did not lower blood flow in plantaris,
soleus, and tibialis muscle of rats 10 weeks of age (Maeda et al.,
2002; Table 1). It should also be noted, though, that other
studies were unable to demonstrate increased forearm flow with
ETA/ETA/B receptor antagonism in volunteers with excessive
weight and type 2 diabetes (Cardillo et al., 2004; Schreuder et al.,
2014; Table 2).
In any case, the increased forearm flow at rest elicited
by ETA receptor antagonism was attributed to underlying
endothelial ETB receptor-mediated dilation because NO synthase
inhibition and ETB receptor antagonism reduced the ETA
receptor antagonist-induced increase in flow, and ETB receptor
antagonism alone decreased flow (Verhaar et al., 1998; Table 2).
Along the general line of the involvement of NO-mitigation
of the decreased flow due to ET-1, in volunteers with
hypercholesterolemia and insulin resistance, ETA, but not ETA/B
receptor antagonism, increased flow (Cardillo et al., 2000;
Shemyakin et al., 2006). Although, in volunteers with type
2 diabetes and aged volunteers, ETA and ETA/B receptor
antagonism elicited similar increases in flow (Cardillo et al., 2002;
Van Guilder et al., 2007). Thus, NO-mitigation of decreased flow
due to ET-1 appears to depend on the disease state.
Exercise
In healthy human volunteers, exercise caused a similar magnitude
of ETA receptor antagonist-induced elevation of forearm blood
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flow as at rest (McEniery et al., 2002; Table 2). In the leg,
in contrast to the lack of ETA receptor antagonist-increased
flow at rest, ETA receptor antagonism increased flow with
exercise (Barrett-O’Keefe et al., 2013, 2015). Hypertension, type
2 diabetes, and age were associated with ETA/ETA/B receptor
antagonist increased flow in forearm and leg with exercise
and were even enhanced as compared to the ETA receptor
antagonism increased flow observed at rest (McEniery et al.,
2002; Barrett-O’Keefe et al., 2013, 2015; Schreuder et al.,
2014; Table 2). Although plethysmography-induced reactive
hyperemia was increased by ETA/B receptor antagonism to
similar magnitudes in healthy and hypertensive volunteers
(Martin et al., 2002; Table 2), it is not clear whether
plethysmography-induced reactive hyperemia mimics the effects
exercise.
In rat, intra-aortic infusion of ETA and ETA/B receptor
antagonists actually resulted in a reduction in flow in tibialis and
plantaris muscle with exercise as compared to rest (Maeda et al.,
2002; Table 1). It should be considered, however, that the reduced
flow was a direct effect of the decreased arterial pressure due
to intra-aortic infusion of ETA and ETA/B receptor antagonist
(Maeda et al., 2002).
The involvement of ET-1 production in exercise is equivocal.
With one-legged exercise, ET-1 production increased in the
non-exercising leg, whereas it was not changed in the exercising
leg (Maeda et al., 1997). Conversely, ET-1 production was
increased during knee exercise-extensor exercise in the exercising
leg (Barrett-O’Keefe et al., 2013). An additional complexity is that
NO formation, which is increased with exercise as demonstrated
through NO synthase inhibition of dilation of the brachial artery
with handgrip (Wray et al., 2011), would be anticipated to
decrease ET-1 production increased by pulsatile shear stress
(Rapoport, 2014b).
Changes in ET-1 contractile sensitivity of the skeletal
muscle vasculature also occur with exercise. Indeed, the
vasoconstrictor influence of infused ET-1 was progressively
reduced with incremental exercise intensity in the leg (Wray et al.,
2007).
Conclusion and Speculation
These findings (Table 2) are consistent with ET-1 as a
dynamic regulator of vascular tone in the skeletal muscle
with exercise. The changes in production and sensitivity
together result in an altered contribution of ET-1 to
skeletal muscle blood flow during exercise. The variable
effects of ET-1 involvement at rest may point to different
degrees of underlying endothelial dysregulation. Indeed,
pathophysiologies associated with endothelial dysregulation also
demonstrate dynamic ET-1 dependency of flow with rest and
exercise.
Lung
Rest
In lying and standing young pig (2–3 months), an intra-
pulmonary artery infused ETA receptor antagonist was without
effect on pulmonary arterial pressure (Merkus et al., 2003,
2007; Houweling et al., 2006; de Beer et al., 2010; Zhou
et al., 2014b; Table 1). While ETA/B receptor antagonism also
did not lower pulmonary arterial pressure in lying pig, in
a number of studies pressure was lowered in standing pig
(Merkus et al., 2003, 2007; Houweling et al., 2006; de Beer
et al., 2010; Zhou et al., 2014b; Table 1). The lack of role of
ET-1 in basal tone in lying pig may be due to ongoing NO
inhibition of ET-1 synthesis because NO synthase inhibition
increased pulmonary vascular resistance and an ETA/B receptor
antagonist prevented the increase (Merkus et al., 2007). Further,
in standing pig (not investigated in lying pig), pulmonary arterial
pressure was reduced by phosphodiesterase-5 inhibition and
ETA/B receptor blockade failed to further reduce pressure in
the presence of phosphodiesterase-5 inhibition (Zhou et al.,
2014b).
Exercise
ETA/B, but not ETA receptor antagonism, prevented exercise-
induced increased pulmonary arterial pressure (Merkus et al.,
2003; Table 1). Thus, it was concluded that the ET-1-
elevated tone during exercise was mediated by (smooth muscle)
ETB receptors (Merkus et al., 2003). Indeed, ETB receptor-
mediated, ET-1-elevated tone of the pulmonary vasculature
during exercise is consistent with ETB receptor mediation of
constriction of pulmonary resistance vessels (MacLean et al.,
1994).
Also, ongoing NO release inhibits the ET-1 increase in
resistance as demonstrated by enhancement of the ETA/B
receptor antagonism-induced decrease in pulmonary arterial
pressure with NO synthase inhibition (Merkus et al., 2007).
Consistent with an underlying role for NO in inhibition
of ET-1 release is lack of further increase in pulmonary
arterial pressure by ETA/B receptor following inhibition of
phosphodiesterase-5 (Zhou et al., 2014b). Furthermore, the effect
of phosphodiesterase-5 inhibition to lower pulmonary arterial
pressure was due to decreased ET-1 synthesis, as demonstrated
by inhibition of big ET-1 constriction in isolated pulmonary
resistance vessels (Zhou et al., 2014b).
Conclusion and Speculation
Consistent with ET-1 as a dynamic regulator of vascular tone
is the ETA/B receptor antagonist reduction of exercise-induced
decreased pulmonary arterial pressure by ETA/B receptor
antagonism (Table 1). The release of ET-1 in response to exercise
is consistent with the ability of moderate levels of pulsatile shear
stress to increase ET-1 release (Rapoport, 2014b).
The lack of effect of ETA/B receptor antagonism on resting
pressure (lying pig) presumably reflects in part lower ET-1 release
due to lesser pulsatile shear stress, i.e., similar to that observed
in splanchnic organs (see section “Splanchnic: Intestine, Kidney,
Spleen, and Stomach”). Another factor involved in the lack of
effect of ETA/B receptor antagonism at rest is NO inhibition of
ET-1 synthesis. While the relative contribution of NO released in
response to endothelial ETB receptor activation and shear stress
is not clear, it may be reasonable to consider that the relative
amount of NO release by endothelial ETB receptor activation is
considerably greater than in the coronary vasculature (see section
“Heart”).
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OVERALL CONCLUSION AND
SPECULATION
These studies demonstrate that ET-1 dynamically regulates
vascular tone with exercise. The resultant changes in blood
flow redistribute flow away from metabolically less demanding
organs/tissue in favor of those with greater demands (Maeda
et al., 2002). By extension, ET-1 alterations of vascular tone
continuously diverts blood flow to organs in response to
even subtle demands, i.e., beyond what is recognized as
“exercise.”
Major factors which influence the ET-1-dependent regulation
of vascular tone are pulsatile shear stress and NO. This
influence occurs through changes in ET-1 synthesis, rather
than direct effects of shear stress and NO on ET-1 contractile
potency. Thus, under conditions of moderate shear stress,
which increases ET-1 release, NO release is also increased,
thereby limiting the release of ET-1 in response to shear
stress (Rapoport, 2014b). NO derived from ET-1-induced,
endothelial ETB receptor activation also acts to limit ET-1
synthesis, although in organs exposed to higher levels of
shear stress, e.g., heart, the relative amount of ETB receptor-
derived NO as compared to shear stress-derived NO may be
minimal.
In possible conflict with ET-1 serving as a dynamic regulator
of vascular tone is the resistance of ET-1 constriction to
reversal (see section “Introduction”). While an explanation
for this apparent conflict is not entirely clear, it should be
noted that the resistance of ET-1 to reversal is based upon
findings with exogenous ET-1. Thus, the effects of exogenous
ET-1 may not entirely mimic those due to endogenous ET-1,
and notably with respect to reversibility of the constriction.
At least along these general lines, despite the numerous
findings of functional (constriction) cross-talk between ETA
and ETB receptors in the normal (physiologic) vasculature as
uncovered with exogenous ET-1 (Rapoport and Zuccarello,
2012), demonstrations of cross-talk with endogenously released
ET-1, at least under physiologic conditions, remain to be
established (to our knowledge).
Possible lack of mimicry of endogenously released ET-1 by
exogenous ET-1 could also involve conditions under which
endogenous ET-1 elicits constriction. In this regard, calcitonin
gene-related peptide (CGRP) selectively reversed constriction
and prevented re-constriction of a number of isolated vessels
(but not all vessels examined) challenged with exogenous ET-1
and terminated the elevated arterial pressure to intravenous
bolus ET-1 injection (Meens et al., 2010, 2011). The CGRP
inhibition of ET-1vasoconstriction was attributed to dissociation
of the quasi-irreversible ET-1-ETA complex (Hilal-Dandan
et al., 1997; Meens et al., 2010). It would be of interest to
investigate whether CGRP selectively prevented/reversed the
ET-1-dependent component of exercise-altered flow and CGRP
receptor antagonists prevented the reversal of these changes in
flow.
Finally, an additional speculative explanation for the apparent
contradiction that ET-1 dynamically regulates vascular tone while
the constriction to (exogenous) ET-1 is resistant to reversal relates
to the dependency of the maintained ET-1 constriction upon
externalization of ETA receptors (Marsault et al., 1993). That
is, the ET-1-ETA receptor complex is rapidly internalized and
the ETA receptor recycled to the cell membrane, whereupon the
receptor is again subject to ET-1 binding (Marsault et al., 1993).
The magnitude of ET-1 constriction at any particular point in
time would, therefore, reflect both reversal due to internalization
of the ET-1-ETA receptor complex and constriction by newly
released ET-1 binding to both previously unbound and recycled
ETA receptors. Thus, reversible ET-1-mediated constriction
could be achieved if the amount of ET-1 release were actually
relatively low, although it has also been speculated that the
(decreasing) fraction of internalized ET-1-ETA receptor complex
is still coupled to signaling (Resink et al., 1990; Chun et al.,
1995).
It is widely recognized that numerous vascular
pathophysiologies are associated with increased ET-1-dependent
tone and, furthermore, that this tone reflects an imbalance
between NO and ET-1 (see section “Introduction”). Indeed, this
imbalance also represents changes in the dynamic regulation of
vascular tone by ET-1, with the balance favoring ET-1 release
(see section “Introduction”). In this regard, ET-1 limitation
of flow with exercise is enhanced in skeletal muscle with
hypertension, hypercholesterolemia, type 2 diabetes and aging
(Hearon and Dinenno, 2016; Table 2) and in the lung in
pulmonary hypertension secondary to myocardial infarction
(Houweling et al., 2006; Merkus et al., 2007), while the ET-1
limitation of flow is reduced in heart with myocardial infarction
(Merkus et al., 2005; de Beer et al., 2011b). While these ET-1-
dependent changes in flow with exercise reflect the differential
influence of numerous vasoactive factors, an understanding of
the detailed mechanism whereby ET-1 release is altered with
exercise will provide further insight into these vascular lesions.
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